New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2012
10:26 EDTPDH, EFC, TWO, HCLP, CYTR, SEE, FNSR, ATR, APKT, BMSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acme Packet (APKT) initiated with a Sector Perform at RBC Capital... AptarGroup (ATR) initiated with a Neutral at JPMorgan... Bemis (BMS) initiated with a Neutral at JPMorgan... CytRx (CYTR) initiated with an Outperform at Rodman & Renshaw... Ellington Financial (EFC) initiated with a Buy at BofA/Merrill... Finisar (FNSR) initiated with a Sector Perform at RBC Capital... Hi-Crush Partners (HCLP) initiated with a Buy at UBS... Hi-Crush Partners initiated with an Outperform at Credit Suisse... PetroLogistics (PDH) initiated with a Buy at Dahlman Rose... Sealed Air (SEE) initiated with an Overweight at JPMorgan... Two Harbors (TWO) initiated with a Buy at BofA/Merrill.
News For APKT;ATR;BMS;CYTR;EFC;FNSR;HCLP;PDH;SEE;TWO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
07:15 EDTBMSBemis sees FY15 adjusted EPS $2.52-$2.67, consensus $2.52
Sees FY15 CapEx $185M-$200M.
07:14 EDTBMSBemis reports Q4 continuing ops EPS 57c, consensus 56c
Reports Q4 revenue $1.05B, consensus $1.05B.
January 23, 2015
08:37 EDTHCLPBofA/Merrill U.S. oil & gas analysts to hold an analyst/industry conference call
Subscribe for More Information
January 22, 2015
09:34 EDTCYTRCytRx to host conference call
Subscribe for More Information
09:09 EDTCYTRCytRx's Aldoxorubicin shows positive Phase 2b results for soft tissue sarcoma
CytRx reported positive overall survival results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas. The OS results in 123 patients demonstrated that aldoxorubicin-treated patients demonstrated a 27% reduction in the risk of death compared to patients treated with doxorubicin, the current standard-of-care in this indication.In addition, aldoxorubicin-treated patients demonstrated a 41% likelihood of surviving more than 2 years, a 2-fold increase, compared to a 20% probability for doxorubicin-treated patients. Median overall survival was 16.0 months for aldoxorubicin-treated patients versus 14.4 months for doxorubicin treated patients. For treatment-naive patients, representing 90% of the patients in the clinical trial, median overall survival was 16.0 months for aldoxorubicin-treated patients versus 14.0 months for doxorubicin treated patients. The positive trend could be significantly improved, now that the FDA has permitted CytRx to dose aldoxorubicin in all trials until tumor progression.
January 20, 2015
09:11 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
06:06 EDTCYTRFDA removes partial clinical hold for CytRx's aldoxorubicin clinical trials
CytRx announced that the FDA has removed the partial clinical hold on the Company's aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites' Institutional Review Boards approve the revised trial protocols. CytRx currently believes that enrollment rates and timelines for its trials will remain materially unchanged. The Company expects to complete enrollment in its ongoing pivotal global Phase 3 trial in second-line soft tissue sarcoma by the end of 2015 and unblind the clinical data by mid-2016. Subject to FDA approval, CytRx's market launch of aldoxorubicin for second line soft tissue sarcoma is projected to commence in 2017.
January 15, 2015
16:32 EDTHCLPHi-Crush Partners raises Q4 dividend 8% to 67.5c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use